ASCO 2019 – Lenalidomide reduces risk that smoldering myeloma will progress to myeloma in high risk patientsConferences, MyelomaMay 31, 2019
Lenalidomide and pomalidomide based triplet combination regimens for myeloma patients receives approval from the European CommissionAccess, MyelomaMay 23, 2019
Call to action for Central and Eastern European (CEE) members – join MPE CEE workgroup on accessAccess, MPEMay 6, 2019
Results of MPE members participation in EMA survey on bortezomibMPE, Myeloma, Patient evidenceMay 3, 2019
